ArticleDiscover oncology2025
Mendelian randomization study on the causal relationships among fasting blood glucose, plasma proteins, and squamous cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSquamous cell lung cancer (SQCLC) represents the second most common subtype of lung cancer (LC) with characteristics of treatment resistance. Plasma proteins often influence levels of fasting blood glucose (FBG), consequently impacting LC. However, the precise role of FBG in this association remains unclear.
objectiveTo investigate the causal relationships of FBG with LC and its subtypes, plasma proteins, and SQCLC, as well as the mediating role of FBG.
methodsMendelian randomization (MR) analysis was employed to assess the causal associations of FBG with LC and its subtypes, plasma proteins and SQCLC, and plasma proteins and FBG, using the two-step MR approach with the primary method being Inverse Variance Weighted (IVW). Protein-Protein Interaction (PPI) network was utilized to identify hub genes of plasma proteins causally linked to SQCLC.
resultsFBG was a risk factor for SQCLC (OR: 1.376, 95% CI 1.017-1.862, P = 0.038) but had no significant causal associations with LC and other subtypes (P > 0.05). Furthermore, 54 plasma proteins had significant causal associations with SQCLC (P < 0.05). EEF2 K (OR: 1.111, 95% CI 1.015-1.216, P = 0.023) and SSR1 (OR: 0.546, 95% CI 0.487-0.613, P < 0.001) were identified as a risk and protective factor for FBG, respectively. Mediation analysis indicated a significant negative mediating effect of FBG in the causal relationship between SSR1 and SQCLC (B = - 0.193, 95% CI - 0.312-0.074, P = 0.001), with a mediation proportion of 44.4%.
conclusionOur study revealed FBG as a risk factor for SQCLC and demonstrated the mediating role of FBG in the causal association between SSR1 and SQCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.